Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: Non-Invasive Manipulation of Intratumoral Genome Editing Potentiates Adoptive T-Cell Therapy against Solid Tumors

PROVIDER: PRJNA930575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23313038_1.fastq.gz	Fastqsanger.gz
	SRR23313038_2.fastq.gz	Fastqsanger.gz
	SRR23313039_1.fastq.gz	Fastqsanger.gz
	SRR23313039_2.fastq.gz	Fastqsanger.gz
	SRR23313040_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Mus musculus

Project description:Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors.

| PRJDB18653 | ENA

Regulatory T cells support breast cancer progression by opposing IFN-γ -dependent functional reprogramming of myeloid cells

Project description:Regulatory T (Treg) cell infiltration of solid tumors often correlates with poor prognosis, but their tumor suppressive function lacks mechanistic understanding. Through a combination of transgenic mice, cell fate mapping, adoptive transfer and co-injection strategies, we demonstrate that Treg cell ablation-dependent anti-tumor effects in murine breast cancer require intratumoral recruitment of CCR2+ inflammatory monocytes, which primarily differentiate into tumor-associated macrophages (TAMs), and lead to reprogramming of their function in an IFN--dependent manner. Furthermore, transcriptomic signatures from murine TAMs in Treg cell-ablated conditions correlate with increased overall survival in human breast cancer. Our studies highlight the strong myeloid dependency of breast cancer, and provide the basis for the development of therapeutic strategies based on manipulation of the IFN- signaling pathway in monocytes.

2020-10-26 | GSE159806 | GEO

Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory [scRNA-Seq]

Project description:CAR T cells have been ineffective against solid tumors, where the hostile tumor microenvironment limits CAR T cell function and persistence. Here we have used CRISPR/Cas9 gene-editing, or a small molecule inhibitor to target protein tyrosine phosphatase N2 (PTPN2) in human CAR T cells specific for the Lewis Y (LeY) neo-antigen. Targeting PTPN2 increased CAR and cytokine signaling and enhanced the activation and cytotoxicity of anti-LeY CAR T cells. The deletion or the systemic inhibition of PTPN2 in human CAR T cells repressed the growth of human tumor xenografts or patient-derived xenografts in mice and prolonged survival. PTPN2 deletion or inhibition promoted the generation and intratumoral accumulation of stem cell memory CD8+ CAR T cells that are associated with persistent CAR T cell-mediated tumor repression and improved clinical outcomes in patients. These findings support the use of gene-editing or small molecule inhibitors for targeting PTPN2 in human CAR T cells to combat solid tumors.

2025-10-04 | GSE309443 | GEO

Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory [RNA-seq]

2025-10-04 | GSE309442 | GEO

AK-098_pmel-BO112

Project description:Bulk Tumor RNAseq after Adoptive T cell Therapy and Intratumoral BO112

2020-10-14 | GSE157351 | GEO

OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors

Project description:OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors

| PRJNA1363200 | ENA

OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors

Project description:OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors

| PRJNA1365650 | ENA

Project description:OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors

| PRJNA1357041 | ENA

Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade

Project description:We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we developed clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenvironment (TME), induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/PDL1 checkpoint inhibition. In vivo, anti-HER2 CAR-M significantly reduced tumor burden, prolonged survival, remodeled the TME, increased intratumoral T cell and natural killer (NK) cell infiltration, and induced epitope spreading. CAR-M therapy protected against antigen-negative relapse in a T cell dependent fashion, confirming long-term anti-tumor immunity. In HER2+ solid tumors resistant to anti-PD1(aPD1) monotherapy, the combination of CAR-M and aPD1 significantly improved tumor growth control, survival, and remodeling of the TME. These results demonstrate synergy between CAR-M and T cell checkpoint blockade and provide a strategy to enhance response to aPD1 therapy for patients with non-responsive tumors.

2024-11-20 | GSE275417 | GEO